

SUSPECT ADVERSE REACTION REPORT													

I. REACTION INFORMATION

1. INITIALS	1a. COUNTRY	2. DATE OF BIRTH			2a. AGE	3. SEX	4-6. REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION <input type="checkbox"/> PATIENT DIED <input type="checkbox"/> LIFE THREATENING <input type="checkbox"/> HOSPITALIZATION <input type="checkbox"/> DISABILITY OR INCAPACITY <input type="checkbox"/> CONGENITAL ANOMALY/BIRTH DEFECT <input type="checkbox"/> OTHER MEDICALLY IMPORTANT CONDITION <input type="checkbox"/> REQUIRED INTERVENTION (MEDICAL DEVICE)			
PRIVACY	PA	Day	Month	Year	39 Year(s)	F	Day	Month	Year				
7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) Event Verbatim [Low Level Term] Developed rash on the hands and legs. [Rash] (10037844 v28.0) - Not serious - Recovered -													

II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) #1 [Suspect] Monofer, 100, Solution for injection (Ferric derisomaltose)						20. DID REACTION ABATE AFTER STOPPING DRUG? <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> NA					
15. DAILY DOSE(S) #1 1000 milligram			16. ROUTE(S) OF ADMINISTRATION #1 Intravenous (not otherwise specified)								
17. INDICATION(S) FOR USE #1 Drug use for unknown indication [Drug use for unknown indication] (10057097 v28.0)						21. DID REACTION REAPPEAR AFTER REINTRODUCTION ? <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> NA					
18. THERAPY DATES (from/to) #1			19. THERAPY DURATION #1								

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUGS(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)											
23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) From / To Dates Description # 1											

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER LABORATORIOS STEIN Escazú, Meridiano Building, 5th floor 10203 San José CR						26. REMARKS					
			24b. MFR CONTROL NO. 2025000339			25b. NAME AND ADDRESS OF REPORTER PRIVACY					
24c. DATE RECEIVED BY MANUFACTURER 01-Jul-2025			24d. REPORT SOURCE <input type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input type="checkbox"/> AUTHORITY <input checked="" type="checkbox"/> HEALTH PROFESSIONAL <input checked="" type="checkbox"/> OTHER								
DATE OF THIS REPORT 16-Jul-2025			25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOW UP :								

7+13. DESCRIBE REACTION(S) continued

Case description : This non-serious case received from a healthcare professional via a partner concerns a 39-year-old female patient who started therapy with MONOFER (ferric derisomaltose), 1000 mg (first dose) on an unknown date due to an unknown indication. The patient was prescribed 2 g of Monofer, divided into 2 doses of 1000 mg. Medical history and concomitant treatment, if any, were not reported.

On an unknown date, 2 days after the infusion of MONOFER had completed, the patient developed developed rash on the hands and legs. Chlorotrimetone and methylprednisolone were administered as treatment. The outcome of the event was recovered on an unknown date.

When the patient was scheduled for the second dose of MONOFER, the patient was premedicated with chlorotrimetone and methylprednisolone, the infusion was completed without reaction.

All information provided in the source document has been added to the narrative. No further information is expected.
Duplicate numbers : PA-NEBO-700519 (NEBO).

14-19. Drugs

#	Name	Dosage Information	Lot/Batch	Route of Admin.	Indication	Therapy dates	Therapy duration
1	[Suspect] Monofer 100 Solution for injection (Ferric derisomaltose)	1000 milligram	UNK	Intravenous (not otherwise specified)	Drug use for unknown indication [Drug use for unknown indication] (10057097 v28.0)		